Global G-Protein Coupled Receptors (GPCR) Market Size

G-protein Coupled Receptors Market Analysis

The Global G-Protein Coupled Receptors Market size is estimated at USD 6.11 billion in 2024, and is expected to reach USD 8.58 billion by 2029, growing at a CAGR of 7.01% during the forecast period (2024-2029).

• The SARS-CoV-2 virus enters the body through the respiratory tract epithelium, mainly the lungs, and spreads to other organs through hematogenous expansion, causing multiorgan injury. The viral vector loading targeting Na+/H+ exchanger regulatory factor 1 (NHERF1) and -arrestin can disrupt the assembly of certain sensory G-protein coupled receptor (GPCR) signalosomes, resulting in disordered cellular responses such as loss of smell and taste.
• This has led researchers to investigate the role of GPCRs in alleviating COVID-19 symptoms. GPCR-targeted drugs have shown potential in reducing the pathogenic symptoms associated with COVID-19, leading to market growth during the initial phase of the pandemic. However, as the pandemic has subsided, research and development activities have slowed down, causing the studied market to lose some traction, but it is expected to have stable growth during the forecast period.
• The G-protein coupled receptors market is anticipated to be driven by the increasing number of cancer cases, cardiovascular infections, and respiratory issues. GPCRs play a crucial role in the development of new medications. According to the American Heart Association's 2021 Journal, more than 130 million adults in the United States are expected to have some type of heart disease by 2035. The Heart and Stroke Foundation of Canada's February 2022 report states that 750,000 people are living with heart failure in Canada, and 100,000 people are diagnosed with this incurable condition each year.
• A press release by Septerna in 2021 mentioned that GPCRs are one of the most prolific drug targets, representing approximately one-third of all approved drugs, and currently extend across all major disease areas. Septerna launched a financing of USD 100 million in January 2022 to advance its emerging pipeline of novel GPCR-targeted drug programs spanning multiple therapeutic areas.
• In April 2021, Tectonic Therapeutic raised USD 80 million in financing to unlock the full potential of GPCR-targeted therapies with biologics. These activities by market players are likely to contribute to market growth over the forecast period. Furthermore, strategic collaborations among market players are expected to boost market growth.
• For example, in December 2022, Sosei Heptares and Eli Lilly launched a drug discovery collaboration to discover, develop, and commercialize small compounds that modify novel G protein-coupled receptor (GPCR) targets related to diabetes and metabolic disorders. In August 2022, Sosei Group Corporation and AbbVie announced a new drug development cooperation and option-to-license agreement to identify, develop, and market small compounds modulating novel G protein-coupled receptor (GPCR) targets linked to neurological illness.
• Despite the market's potential for growth, the high cost involved in maintaining GPCR cell lines and the complexity of the GPCR signaling system may impede market growth.